Grifols, Inc. (NASDAQ: GRFS) is a global healthcare company specializing in the development, manufacture and marketing of plasma-derived medicines, diagnostic systems and hospital supplies. With a core focus on immunotherapy and transfusion medicine, the company harnesses human plasma proteins to create therapies that treat a wide range of bleeding disorders, immunodeficiencies and neurological conditions. Grifols also supplies reagents and diagnostic instruments for transfusion centers and clinical laboratories, alongside intravenous solutions and medical devices for hospital use.
The company operates three main business units. The Bioscience division processes plasma to produce therapies such as immunoglobulins, albumin and coagulation factors. Its Diagnostic unit offers blood typing reagents, molecular diagnostic systems and pathogen detection technologies designed to enhance blood safety and screening. The Hospital group provides parenteral nutrition, intravenous solutions and medical devices used in surgical and critical care settings. Together, these segments support hospitals, blood banks and healthcare providers around the world.
Founded in Barcelona in 1940 by Dr. José Antonio Grífols Roig, Grifols began as a small laboratory before evolving into one of the largest plasma collection and fractionation companies worldwide. It expanded its global footprint through strategic acquisitions, including plasma collection networks in North America and Europe, and the acquisition of Talecris Biotherapeutics in 2011. The company has been publicly traded on the NASDAQ since 2006, underscoring its commitment to transparency and growth in international markets.
Headquartered in Barcelona, Spain, Grifols maintains a presence in more than 100 countries through an extensive network of donation centers, manufacturing plants and research facilities. Under the leadership of Chief Executive Officer Raimon Grifols Roura, the company continues to invest in research and development, with ongoing clinical programs aimed at advancing novel therapies and diagnostic solutions. Grifols remains dedicated to improving patient outcomes and addressing global healthcare challenges through innovation in plasma-based medicine.
AI Generated. May Contain Errors.